Lake Street analyst Eric Martinuzzi maintained a Buy rating on OptimizeRx (OPRX – Research Report) today and set a price target of $17.00. The company’s shares closed last Friday at $10.81.
Martinuzzi covers the Technology sector, focusing on stocks such as Par Technology, Brightcove, and Quantum. According to TipRanks, Martinuzzi has an average return of 0.5% and a 39.68% success rate on recommended stocks.
OptimizeRx has an analyst consensus of Strong Buy, with a price target consensus of $16.17.
OPRX market cap is currently $196.6M and has a P/E ratio of -10.60.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OptimizeRx (OPRX) Company Description:
OptimizeRx Corp. engages in the provision of digital health messaging via electronic health records, which serves as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers EHR workflow solutions which include financial messaging, patient education, and brand messaging; and brand support. The company was founded by David A. Harrell on November 8, 1985 and is headquartered in Rochester, MI.
Read More on OPRX:
- OptimizeRx to Participate in Upcoming Investor Conferences
- OptimizeRx Provides Business Update and Sets First Quarter 2024 Conference Call for May 14, 2024 at 4:30 p.m. ET
- OptimizeRx sees Q1 revenue $18.5M-$19.2M, consensus $17.03M
- OptimizeRx Releases 2024 Environmental, Social, and Governance (ESG) Report
- Navigating New Horizons: Optimizerx Corporation’s Strategic Pivot Raises Financial Risk Flags
